Seqirus has made it known that its new cell-based seasonal influenza vaccine Flucelvax Tetra has been approved by the European Commission for patients over the age of nine, making it the first cell-based quadrivalent influenza vaccine (QIVc) available in Europe.
The EC’s decision on the vaccine was made “on the basis of immunogenicity and safety” compared to a cell-based trivalent vaccine.
